Cargando…
Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells
Use of the antibody trastuzumab to kill HER2+ breast cancer cells is an attractive therapy because of its specificity and minimal adverse effects. However, a large fraction of HER2+ positive patients are or will become resistant to this treatment. No other markers are used to determine sensitivity t...
Autores principales: | Kute, Timothy, Stehle, Jr., John R., Ornelles, David, Walker, Natalie, Delbono, Osvaldo, Vaughn, James P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489736/ https://www.ncbi.nlm.nih.gov/pubmed/23162748 http://dx.doi.org/10.4161/onci.20447 |
Ejemplares similares
-
The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC
por: Guti, Eliza, et al.
Publicado: (2022) -
Development of a Macrophage-Based ADCC Assay
por: Uccellini, Melissa B., et al.
Publicado: (2021) -
Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar
por: Kim, Seokkyun, et al.
Publicado: (2017) -
ADCC potency assay: increased standardization with modified lymphocytes
por: Bretaudeau, Laurent, et al.
Publicado: (2011) -
Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era
por: Mandó, Pablo, et al.
Publicado: (2021)